1. Research
Genomics Institute image

Icahn Genomics Institute

RESEARCH

Research

The Icahn Genomics Institute (IGI) is dedicated to the development of new DNA and RNA based therapies. The success of the mRNA vaccines for treating COVID-19 has had a profound effect on the world—yet this is only the tip of the iceberg of gene medicine. The IGI is working on the next generation of advances in gene therapy, including identifying new genetic targets that drive disease, developing delivery mechanisms to modify or influence them, and pioneering treatments for diseases that have defied conventional treatment by traditional drugs. Our exploration of gene and cell therapy, RNA vaccines and therapeutics, and DNA-based drugs will have a profound effect on the way medicine is practiced.

Housed within the Icahn School of Medicine at Mount Sinai, we are working together with physicians and physician scientists in the Mount Sinai Health System. From bench to clinical practice, we are leading the way in bringing the latest generation of gene and cell therapies to our patient population, including chimeric antigen receptor (CAR) T cell therapies and in situ vaccines for leukemia and multiple myeloma, and RNAi drugs for diseases such as acute intermittent porphyria, and other life-long genetic diseases. In doing so, we are helping to improve the lives of our patients and transforming medicine.

Person headshot

Brian D Brown, PhD
VICE CHAIR | Immunology & Immunotherapy
DIRECTOR, ICAHN GENOMICS INSTITUTE
ASSOCIATE DIRECTOR OF THE PRECISION IMMUNOLOGY INSTITUTE
PROFESSOR | Genetics and Genomic Sciences
PROFESSOR | Dermatology
PROFESSOR | Immunology & Immunotherapy

Dr. Brian Brown is an immunologist and molecular biologist whose research has a strong focus on biotechnology and therapeutics. His training...

AT A GLANCE

Research at the Icahn Genomics Institute 

5324
Publications
2752
Press/Media

54 Researchers

Researchers Image 1
Researchers Image 2
Researchers Image 5
Researchers Image 6
View All Researchers

Recent Publications

Aminoadipate-semialdehyde synthase, a potential target for substrate reduction therapy in glutaric aciduria type 1. Scientific Reports

Author Correction A streamlined base editor engineering strategy to reduce bystander editing (Nature Communications, (2025), 16, 1, (8115), 10.1038/s41467-025-63609-6). Nature Communications

Author Correction Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors (Communications Medicine, (2026), 6, 1, (1), 10.1038/s43856-025-01230-w). Communications Medicine

View Full Details

Discover the Latest

RNA Biomarkers
Mount Sinai Researchers Identify RNA Biomarkers that Could Offer a Simple Blood Test for Earlier Alzheimer’s Diagnosis
Test tubes
New Research Challenges Understanding of mRNA Vaccines and Establishes Innovative Way to Make Them More Effective
See All News

Resources For You

Department of Genetics and Genomic Sciences
Medical Genetics and Genomics
Marc and Jennifer Lipschultz Precision Immunology Institute